Design Therapeutics (DSGN) Equity Average (2020 - 2026)

Design Therapeutics' Equity Average history runs 7 years deep, the most recent figure standing at $215.3 million for Q1 2026.

• In Q1 2026, Equity Average fell 8.4% year-over-year to $215.3 million; the TTM figure through Mar 2026 stood at $215.3 million (down 8.4% YoY), while the FY2025 annual figure was $227.3 million, down 12.54% from the prior year.
• Equity Average came in at $215.3 million for Q1 2026 at Design Therapeutics, up from $206.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $376.2 million in Q1 2022 to a low of $206.1 million in Q4 2025.
• A 5-year average of $279.2 million and a median of $273.6 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average soared 89.68% in 2022 and declined 19.65% in 2025, its largest moves.
• Design Therapeutics' Equity Average stood at $334.1 million in 2022, then declined by 15.8% to $281.3 million in 2023, then declined by 12.1% to $247.3 million in 2024, then dropped by 16.65% to $206.1 million in 2025, then gained by 4.45% to $215.3 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $215.3 million, $206.1 million, and $206.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison